Related news BREAKING: Stocks Bounce But Tumble For Week Pharma stocks can be the most rewarding of all equities. And BeOne Medicines (ONC) is currently offering a chance for new investors to climb on board amid a powerful rally in 2025. The Switzerland-based company – previously named BeiGene – develops immunotherapies to fight cancer. It was founded in China, but had a spell where it was headquartered in the… IBD Videos Get market updates, educational videos, webinars, and stock analysis. Get Started Lear ...

Share BRUKINSA now demonstrates best-in-class sustained efficacy and long-term benefit with a favorable safety profile over more than six years of follow-up data in treatment-naïve and R/R CLL First results from Phase 1/2 sonrotoclax monotherapy study will demonstrate notable speed and depth of clinical responses in patients with R/R MCL, a rare, aggressive cancer New efficacy and safety data will highlight the benefits of potential first-in-class BTK degrader BGB-16673 in patients across multiple hematolog ...

Summary of b one Company Conference Call Company Overview - **Company**: b one Company - **Industry**: Biotechnology Key Points and Arguments 1. **Global R&D Network**: b one Company has established a global R&D network and independent clinical trials, significantly reducing drug development costs and improving efficiency, particularly in areas that other companies are not interested in or unable to enter [2][4][6] 2. **Leadership in Protein Degradation**: The company is a leader in the protein degradation field with multiple projects in clinical stages and has built manufacturing capabilities for bioproducts, enhancing cost-effectiveness and time advantages in R&D and commercialization [2][6] 3. **Revenue Growth**: In Q3 2025, over 50% of b one Company's business came from the U.S., with European business growing by 71% year-over-year, accounting for 12% of total sales. Other markets, such as Japan, saw rapid growth of 133% year-over-year [2][7] 4. **CLL Drug Development**: b one Company is focused on developing high-quality drugs in the Chronic Lymphocytic Leukemia (CLL) field, including approved BTK inhibitor Bruton’s and BCL-2 inhibitors, which show significant efficacy in clinical trials [2][8] 5. **Clinical Trials Strategy**: The company is conducting head-to-head Phase III clinical trials for PCL2 and PDK to validate the superiority of its drugs, a strategy that has been historically employed and will continue in the future [2][8] 6. **R&D Capabilities**: b one Company has a diverse R&D portfolio, including small molecules and ADCs, and is recognized as one of the most accomplished R&D companies in protein degradation, with three projects in clinical stages and 20 in preclinical stages [6][12] 7. **Financial Performance**: In 2025, b one Company achieved operational profitability with a net profit of $125 million and free cash flow of $354 million, indicating strong financial health [14][15] 8. **AI in Drug Discovery**: The company is leveraging artificial intelligence in drug discovery and development, particularly in protein structure folding and manufacturing process optimization, with a focus on improving data quality and real-world data acquisition [16] Additional Important Information 1. **Upcoming Approvals**: b one Company anticipates that surrender clocks will receive preliminary approval in the U.S. and globally in 2026, while the BTK degrader is expected to achieve market approval in 2027 [9][10] 2. **Fixed Duration Treatment Data**: Recent data on fixed-duration treatment in CLL shows significant effectiveness, with a combination therapy achieving a milestone of progression-free survival at three years with only 15 months of treatment [9] 3. **Expansion in Solid Tumors**: The company has introduced 16 new molecular entities into clinical trials, focusing on solid tumors, with CDK4 inhibitors showing higher-than-expected response rates in first and second-line treatment settings [10][11] 4. **Balance of Investments**: b one Company aims to balance internal R&D investments with external asset acquisitions, focusing on sustainable growth while maintaining high standards in project selection [14][15]

PresentationYuxi DongJefferies LLC, Research Division All right. Good afternoon, everyone. Thanks for joining us here for Jefferies Global Healthcare Conference in London. My name is Clara Dong. I'm a biotech analyst here at Jefferies. So it's my absolute pleasure to have the BeOne team here joining us here on the stage. We have CEO of BeOne, John Oyler; Aaron Rosenberg, CFO; and Mark Lanasa, the Chief Medical Officer of Solid Tumor. Welcome. ...

Zymeworks Inc. (NASDAQ:ZYME) stock is surging on Monday, with a session volume of 2.17 million, compared to an average volume of 728.75K, according to Benzinga Pro.Zymework, along with its partners, Jazz Pharmaceuticals Inc. (NASDAQ:JAZZ) and BeOne Medicines Inc. (NASDAQ:ONC) , announced topline results from the Phase 3 HERIZON-GEA-01 trial.The study evaluated Ziihera (zanidatamab-hrii) in combination with chemotherapy, with or without BeOne’s Tevimbra (tislelizumab), as a first-line treatment for HER2-posi ...

Core Viewpoint - The article highlights the significant financial performance of BeiGene, showcasing its successful global business strategy and marking a milestone in the profitability of Chinese innovative pharmaceutical companies in the oncology sector [2]. Financial Performance - In Q3 2025, BeiGene reported total revenue of $1.4 billion, a 41% increase year-over-year, achieving a historical high for the same period. The net profit was 689 million yuan, marking a turnaround from losses [1]. - For the first three quarters of 2025, revenue reached 27.595 billion yuan, up 44.2% year-over-year, with a net profit of 1.139 billion yuan, also a turnaround from losses [1]. Product Performance - The BTK inhibitor, Zanubrutinib, achieved global sales of $1.039 billion in the quarter, a 51% increase year-over-year, entering the "blockbuster" drug category and becoming the highest-grossing product in its class [2]. - In the U.S. market, Zanubrutinib sales reached $739 million, a 47% increase year-over-year, with a growing market share and a leading position in new patient acquisition [2]. - In Europe, Zanubrutinib's sales surged to $163 million, a 68% increase year-over-year, with full inclusion in health insurance in major countries like Germany, Italy, and France [2]. Regulatory Approvals and Clinical Trials - Zanubrutinib is approved for five indications, including chronic lymphocytic leukemia and mantle cell lymphoma, with ongoing expansion into new indications such as primary membranous nephropathy [3][4]. - The company has also made significant progress with its PD-1 product, Tislelizumab, which received EU approval for use in non-small cell lung cancer [4]. Future Outlook - BeiGene has raised its revenue guidance for the year from $5-5.3 billion to $5.1-5.3 billion, driven by the continued growth of Zanubrutinib and its expansion in Europe and other regions [7]. - The company anticipates several important developments in 2026, including potential orphan drug designation for Zanubrutinib in Japan and further clinical trials for its other products [7][8]. - The revenue potential for BeiGene remains substantial, with upcoming data readouts expected to drive future growth [9].

BREAKING: Futures Rise After Growth-Led Market Sell-Off BeOne Medicines ADR BeOne Medicines ADR ONC $ 377.47 $33.82 9.84% 223% IBD Stock Analysis Stock breaking out from flat base ONC RS line hits 52-week high on weekly chart Composite Rating 97/99 Industry Group Ranking 4/197 Emerging Pattern Flat Base Flat Base One of three positive chart patterns to look for when doing technical analysis. It usually occurs after… Related news Dow Dives 800 Points In Sharpest Loss In A Month, With Market's AI Names Nvidia ...

BREAKING: Futures Rise After Growth-Led Market Sell-Off On Wednesday, BeOne Medicines (ONC) stock received an upgrade to its Relative Strength (RS) Rating, from 89 to 92. Â Here Are 3 Keys For Successful Stock Investing This exclusive rating from Investor's Business Daily identifies share price action with a 1 (worst) to 99 (best) score. The grade shows how a stock's price performance over the last 52 weeks… Related news Get market updates, educational videos, webinars, and stock analysis. Get Started Learn ...

Summary of B One Pharmaceuticals Conference Call Company Overview - B One Pharmaceuticals has a vertically integrated clinical development system with over 3,600 professionals, accelerating drug market entry [2][3][4] Key Points and Arguments Clinical Development and Pipeline - The company plans to initiate a pivotal trial for the CDK4 project in mid-2026 [2] - The Celestial trial for CLL patients was completed in just 14 months, showcasing efficient clinical advancement capabilities [2][4] - Brukinder, a BTK inhibitor, shows a 72% progression-free survival (PFS) at 72 months, improving to 77% after adjusting for COVID factors [2][4] - Significant market growth observed: China up 47% YoY, Europe up 71% YoY [2][4] Treatment Strategies - B One supports fixed-duration treatments that meet specific criteria: deep response (umrd), sustained PFS, good safety, and convenience [2][5] - The combination of Sorrow and Perkins A is expected to meet these standards, expanding market reach and addressing various patient needs [2][5] - The new BCL-2 inhibitor, Sun Rotoclass, is anticipated to have broader application potential [2][5] Competitive Positioning - The addition of the Celestial 301 study aims to eliminate market biases and ensure Brukinder's competitive edge against Calquence [2][6] - The study is designed to provide a fixed-duration regimen that ensures comparable or superior long-term outcomes for patients [2][6] Market Dynamics - The introduction of non-covalent BTK inhibitors is expected to significantly alter the market landscape [2][7] - Initial data from the Alps trial indicates a response rate difference of about 12% in relapsed or refractory patients, with over 20% in the aggressive 17p deletion cohort [2][7] B2K Business Strategy - B One's B2K strategy focuses on the BTKC DAC molecule, a catalytic degrader that effectively degrades the entire BTK protein while maintaining activity against kinase domain mutations [2][8] - Key phase II studies show an 84% response rate in heavily pre-treated patients, with a 79% 12-month PFS [2][8] Upcoming Developments - At the upcoming ASH meeting, B One will present new data on BTKC DAC across various malignancies, including CLL [2][9] - The product Sonora, designated for relapsed/refractory MCL, is expected to show higher efficacy and a larger therapeutic window compared to existing treatments [2][9][10] - A phase III trial for multiple myeloma is planned for next year, exploring Sun Rotor Clarks as part of a combination therapy [2][10] CDK4 Inhibitor Project - The CDK4 inhibitor project is prioritized for first-line breast cancer trials due to promising early data and less competition in the first-line setting compared to the second-line market [2][10] - Early data shows a high response rate similar to Pfizer's CDK4 inhibitor, with plans to provide further data next year [2][10] Additional Important Information - B One has successfully advanced 26 internally developed candidates into clinical trials since 2004, highlighting its strong discovery capabilities [2][3] - The company recognizes the critical importance of the clinical development phase and has invested in building a comprehensive clinical development system [2][3]

Related news BREAKING: Two Big Space Stock Winners Deliver Earnings Investors.com will undergo scheduled maintenance from 10:00 PM ET to 2:00 AM ET and some features may be unavailable. We apologize for any inconvenience. Biotech leader BeOne Medicines (ONC) regained a key level in recent sessions and is approaching its latest buy point. That makes BeOne Tuesday's pick for IBD 50 Growth Stocks To Watch. BeOne Medicines is the new name for BeiGene, a biotech company founded in 2010 with employees in the U.S. ...